

**HOT  
NEWS**

## IN HEMATOLOGY

Sindromi  
linfoproliferative  
ed oltre...

### **CASO CLINICO**

**Dr.ssa De Candia Maria Stella**

IRCCS – Istituto Tumori BARI

**BARI**

**7 luglio 2022**

Villa Romanazzi Carducci

## Disclosures of Maria Stella De Candia

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
No disclosures							


## B.V , donna , 84 anni

### Anamnesi:

- Ipertensione arteriosa
- Sindrome depressiva lieve
- Giugno 2021 Insorgenza edema braccio dx e mammella dx → Riscontro ecografico di linfadenomegalie in sede ascellare dx (diam 5 cm)
- Biopsia linfonodale : Linfoma non Hodgkin mantellare, variante blastoide. Stadio II (ascellare dx +retrovracaveare dx + retropettorale dx e mediastino anteriore)

MIPI: high

OS mediana 29 mesi




Agosto 2021: Inizia terapia secondo schema Rituximab-bendamustina

**Table 1**  
Chemotherapy-based initial therapy for older mantle cell lymphoma patients

Regimen	Phase	N	Age (Year) (Range)	Overall Response Rate (Complete Response/Unconfirmed Complete Response)	Progression-Free Survival	Overall Survival	Notable Adverse Effect Profiles Greater Than or Equal to Grade 3	
R-CHOP based	MCL Elderly: R-CHOP/IR	III	267	70 (60–87)	86% (34%)	mPFS, 5.4 y	mOS, 9.8 y	Thrombocytopenia, 57% Neutropenia, 15%
	LYM-2003: VR-CAP	III	243	65 (26–88)	92% (53%)	mPFS, 25 mo	mOS, 90.7 mo	Febrile neutropenia, 15% Thrombocytopenia, 1% Febrile neutropenia, 1% Neuropathy, 8%
BR based	StiL: BR	III	46	64 (34–83)	93% (40%)	mPFS, 35 mo	N/R	Thrombocytopenia, 6% Neutropenia, 29% Skin rash (all grades), 15%
	BRIGHT: BR	III	36	60 (28–84)	94% (50%)	5-y PFS, @ 40%	5y-OS, @ 59%	Thrombocytopenia, 10% Neutropenia, 39%
	FIL: R-BAC	II	57	71 (67–75)	91% (91%)	3-y PFS, @ 76%	N/R	Skin rash (all grades) 20% Thrombocytopenia, 52% Neutropenia, 49%
	LYSA: RiBVD	II	74	73 (64–83)	84% (75.5%)	4-y PFS, @ 58%	4-y OS, @71%	Febrile neutropenia, 8% Thrombocytopenia, 35% Febrile neutropenia, 15% Neuropathy, 15%
	NLG/MCL4: LBR	I/II	51	71 (62–84)	80% (64%)	mPFS, 42 mo	3-y OS, @73%	Thrombocytopenia, 20% Neutropenia, 75% Infections, 42%

Abbreviations: LBR, lenalidomide, bendamustine, rituximab; mOS, median overall survival; mPFS, median progression free survival; N/R, not reported; @, at. Data from Refs.<sup>4-7,12-17</sup>



Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma  
Jia Ruan. Hematol Oncol Clin N Am 34 (2020) 871–885

A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

Trial on going...

Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-cell Lymphoma  
M.L. Wang, NEJM 2022


TAC di rivalutazione dopo 4 cicli: RP

Gennaio 2022: polmonite interstiziale bilaterale da COVID 19. Effettuata terapia con Anticorpi monoclonali per covid19.

Episodio di FA parossistica durante la degenza ospedaliera: inizia terapia con NAO e betabloccanti

TAC torace febbraio 2022: incremento volumetrico delle già note linfoadenomegalie

Quale terapia?



## BTK approvati da FDA :

- Ibrutinib
- Acalabrutinib
- Zanubrutinib

## BTK approvati da AIFA:

- Ibrutinib

Protocol Used	Number of Patients/ Overall Number	Median Follow-up	ORR (CR) %	TTF/PFS	OS	Comments
<b>Relapsed MCL</b>						
Ibrutinib <sup>53</sup>	36/370	3.5 y	50/NA	5.1 mo	12.8 mo	<ul style="list-style-type: none"> <li>• Time to best response was similar in blastoid vs nonblastoid MCL</li> <li>• Duration of response was 8.5 vs 18.8 mo in blastoid and nonblastoid MCL</li> </ul>
Ibrutinib + rituximab <sup>64</sup>	7/49	4 y	71/43	21 mo	30 mo	Relapsed patients with blastoid MCL have inferior outcomes and lower response rates compared with nonblastoid MCL, albeit number of patients with blastoid MCL was small
Acalabrutinib <sup>55</sup>	26/124	2 y	77/35	15 mo	NA	Response rates and outcomes were inferior in blastoid compared with nonblastoid MCL


Summary of pivotal clinical studies in blastoid/pleomorphic mantle cell lymphoma

Hematol Oncol Clin N Am 34 (2020)

## Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Blood 2022

	Classic histology (n = 68)	Blastoid histology (n = 12)
ORR	86.8 (76.4-93.8)	66.7 (34.9-90.1)
CR	79.4 (67.9-88.3)	66.7 (34.9-90.1)
Median DOR, mo	30.2 (19.5-NE)	30.6 (7.2-NE)
Median PFS, mo	27.8 (16.8-NE)	25.0 (2.5-NE)
36-mo OS	77.5 (64.8-86.0)	50.0 (20.8-73.6)




Ritornando alla nostra paziente..

Febbraio 2022 inizia terapia con Ibrutinib + monitoraggio cardiologico (ECG)

Giugno 2022 riduzione delle dimensioni delle linfoadenomegalie (RP), quadro cardiologico stazionario, prosegue terapia con ibrutinib.


**Grazie per l'attenzione!**

A horizontal banner image featuring a microscopic view of cells. The left side is blue with a white box containing the text 'HOT NEWS'. The middle and right sides show a transition from blue to red, with various cell types visible, including some with prominent nuclei and others that are more elongated or fibrous.

**HOT  
NEWS**

**IN HEMATOLOGY**  
Sindromi linfoproliferative  
ed oltre...

**Bari, 7 Luglio 2022**  
Villa Romanazzi Carducci

A horizontal banner image featuring a microscopic view of cells. The left side is blue with a white box containing the text 'HOT NEWS'. The middle and right sides show a transition from blue to red, with various cell types visible, including some with prominent nuclei and others that are more elongated or fibrous.

**HOT  
NEWS**

**IN HEMATOLOGY**  
Sindromi linfoproliferative  
ed oltre...

**Bari, 7 Luglio 2022**  
Villa Romanazzi Carducci